Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 17/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4488430 | 0.90 | SRC (0.43) | SRC | |
| SCHEMBL4495142 | 0.88 | SRC (0.41) | SRC | |
| SCHEMBL4503178 | 0.88 | SRC (0.40) | SRC | |
| SCHEMBL13818399 | 0.86 | SRC (0.36) | SRC | |
| SCHEMBL4488891 | 0.86 | SRC (0.37) | SRC | |
| SCHEMBL4505004 | 0.82 | SRC (0.33) | SRC | |
| SCHEMBL4506069 | 0.78 | SRC (0.48) | SRC | |
| SCHEMBL4506077 | 0.78 | SRC (0.48) | SRC | |
| SCHEMBL4506074 | 0.78 | SRC (0.48) | SRC | |
| SCHEMBL4481471 | 0.77 | METAP1 (0.45) | SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550453-B2 | Anticancer agents; colon cancer or hepatocellular carcinoma; analogs of bengamide where the caprolactam ring is changed and/or substituted e.g. N-(2-Methyl-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepin-4-yl)-(E)-(2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide | AVENTIS PHARMA SA (FR) | 2009-06-23 | — | — | US | disclosed |
| US-20070244087-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDES, PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244087-A1 | 2-ALKOXY-3,4,5-TRIHYDROXY-ALKYLAMIDES, PREPARATION THEREOF, COMPOSITIONS CONTAINING THEM AND USE THEREOF | HCCS, ALKBH2, ALKBH3 | SRC 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.